Lupeol

Name of the	Lupeol				
Phytochemical					
Chemical Structure	$H_{2}C$ $H_{3}C$ H				
Botanical	Crataeva nurvala				
Source					
CAS Number	545-47-1				
Functional Activity	 Potent anti-inflammatory, anti-carcinogenic, anti-mutagenic, and anti-malarial activity. An effective Androgen Receptor inhibitor, can be developed as a potential agent to treat human prostate cancer (CaP). It suppresses the growth of hepatocellular carcinoma cell lines SMMC7721 and HepG2 with IC₅₀values of 45 and 48.5 μM and melanoma cell lines Mel 928 and Mel 1241 with IC₅₀ values of 75 and 72 μM. It has been tested for its therapeutic efficiency against conditions including wound healing, diabetes, cardiovascular disease, kidney disease, and arthritis 				
Key References	 Clinical systemic lupeol administration for canine oral malignant melanoma, Molecular and clinical oncology, 2015, 3, 89-92 Non- surgical treatment of canine oral malignant melanoma. A case study of the application of complementory alternative medicine, Oncol Lett. 2014, 7, 1829-1830 Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy, Clin Cance Res. 2011, 17, 5379-5391 Clinical Trial of Lupeol for Mild-moderate Acne, https://clinicaltrials.gov/ct2/show/NCT02152865 Clinical Study for Topical Lupeol in Acne (https://clinicaltrials.gov/ct2/show/NCT02205892) 				